SCHEMBL5118925

SCHEMBL5118925

Cc1c(Cl)ccc(S(=O)(=O)CNCCCC(=O)O)c1Cl

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FABP4 P15090 4/20 0.43
CA1 P00915 4/20 0.42
CA2 P00918 4/20 0.42
WDR5 P61964 1/20 0.41
CDC25A P30304 2/20 0.40
CDC25B P30305 2/20 0.40
CA12 O43570 2/20 0.38
CA3 P07451 2/20 0.38
CA4 P22748 2/20 0.38
CA6 P23280 2/20 0.38
CA5A P35218 2/20 0.38
CA7 P43166 2/20 0.38
CA9 Q16790 2/20 0.38
CA13 Q8N1Q1 2/20 0.38
CA14 Q9ULX7 2/20 0.38
CA5B Q9Y2D0 2/20 0.38
GAA P10253 1/20 0.36
S1PR1 P21453 2/20 0.35
S1PR3 Q99500 2/20 0.35
S1PR2 O95136 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5113650 0.96 FABP4 (0.47) FABP4CA1CA2WDR5CDC25A
SCHEMBL3992993 0.82 WDR5 (0.40) WDR5CDC25AGAAALDH1A1ATM
SCHEMBL5111162 0.82 CDC25A (0.45) FABP4CA1CA2CDC25ACDC25B
SCHEMBL4464905 0.81 WDR5 (0.39) FABP4WDR5ALDH1A1ATMLMNA
SCHEMBL6763197 0.79 WDR5 (0.40) CA1CA2WDR5ATMLMNA
SCHEMBL5115200 0.78 FABP4 (0.46) FABP4CDC25ACDC25BALDH1A1LMNA
SCHEMBL15577096 0.77 WDR5 (0.37) WDR5ALDH1A1ATMLMNA
SCHEMBL5118262 0.76 WDR5 (0.40) WDR5ALDH1A1ATMLMNA
SCHEMBL5118265 0.76 WDR5 (0.40) WDR5ALDH1A1ATMLMNA
SCHEMBL5117224 0.75 FABP4 (0.51) FABP4CA1CA2CDC25ACDC25B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7361687-B2 Arylsulphonamide derivatives and methods of preparing LABORATOIRES FOURNIER SA (FR) 2008-04-22 US disclosed
US-20060084699-A1 Novel arylsulphonamide derivatives and use thereof as therapeutic agents LABORATOIRES FOURNIER SA (FR) 2006-04-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060084699-A1 Novel arylsulphonamide derivatives and use thereof as therapeutic agents UGT1A1, UGT2B7, UGT1A6 FABP4 2346/4885CA1 4872/4885CA2 4757/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.